The European Medicines Agency has recommended granting pan-EU marketing approval to 14 new products, including Valneva’s chikungunya vaccine Ixchiq and Pfizer/Spark Therapeutics’ hemophilia B gene therapy Durveqtix (fidanacogene elaparvovec).
If approved, Ixchiq will become the first vaccine in the EU to protect adults 18 years and older against chikungunya....








